EUVIMEDEUVIMED entdecken
Crossref

Stakeholder Perspectives on Potential Open-Label Bias in Patient-Reported Outcome Results From Cancer Clinical Trials: Evidence From the IMPROvE Project

Fabio Efficace, Daniela Krepper, Francesco Sparano, Neil K Aaronson, David Cella, Gary S Collins, Johannes M Giesinger, Rajshekhar Chakraborty, Massimo Di Maio, Amelie Anota

Value in Health · 2026-11 · 29 (11) · 2044-2053

DOI: 10.1016/j.jval.2026.06.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-11. Verfasst von Fabio Efficace und 9 weiteren Autor:innen. Beteiligte Einrichtung: Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. Electronic address: f.efficace@gim…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Neoplasms, Randomized Controlled Trials as Topic, Stakeholder Participation. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Daiichi Sankyo Europe GmbH, Fondazione GIMEMA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To explore stakeholder perspectives related to open-label bias in patient-reported outcomes (PROs) from cancer randomized controlled trials and identify possible risk factors for such bias. This study represents the first phase of the Importance of Patient-Reported Outcomes in Cancer Clinical Trials: Evaluating the Effects of Therapy Masking (IMPROvE) project, an international initiative investigating the impact of trial design (ie, open-label vs blinded trials) on PRO results. METHODS: Semistructured interviews were conducted with 20 stakeholders, including PRO experts (researchers, oncologists, and statisticians) and patients from 7 countries. An interview guide addressed perceptions, experiences, and views on potential contributors of open-label bias in PROs. Thematic content analysis was used to identify recurrent themes and patterns. Findings were complemented with a targeted narrative literature review. RESULTS: Stakeholders expressed divergent views regarding the presence and magnitude of open-label bias in PROs. Patient expectations, treatment type, disease stage, and clinician-patient interactions were frequently mentioned as potential contributors to such bias. Although experts often framed open-label bias as a methodological concern, patients highlighted experiential and relational aspects. Both groups acknowledged that robust trial methodology and validated PRO instruments may mitigate risks. Literature findings were consistent with these perspectives, highlighting careful methodological planning and transparent reporting practices as critical to mitigate risk of bias. CONCLUSIONS: This study offers insights into stakeholder perspectives on potential open-label bias in PROs from cancer randomized controlled trials, highlighting both methodological and experiential dimensions. These exploratory findings may inform future evidence generation and guide the development of an "open-label bias PRO checklist."

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresNeoplasmsRandomized Controlled Trials as TopicStakeholder ParticipationHumansBiasFemaleResearch DesignMaleInterviews as Topic

Stichwörter der Autor:innen

clinical trialsopen-label biaspatient-reported outcomes

Autor:innen und Institutionen

  • Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy. Electronic address: f.efficace@gimema.it.
  • Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy; University Hospital of Psychiatry II, Medical University of Innsbruck, Innsbruck, Austria.
  • Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
  • Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Department of Applied Health Sciences, School of Health Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, UK; NIHR Biomedical Research Centre: Birmingham, University Hospitals Birmingham NHS…

Förderung

  • Daiichi Sankyo Europe GmbH
  • Fondazione GIMEMA

Zitieren

APA

Efficace, F., Krepper, D., Sparano, F., Aaronson, N. K., Cella, D., Collins, G. S., Giesinger, J. M., Chakraborty, R., Di Maio, M., & Anota, A. (2026). Stakeholder Perspectives on Potential Open-Label Bias in Patient-Reported Outcome Results From Cancer Clinical Trials: Evidence From the IMPROvE Project. Value in Health, 29(11), 2044-2053. https://doi.org/10.1016/j.jval.2026.06.002

Vancouver

Efficace F, Krepper D, Sparano F, Aaronson NK, Cella D, Collins GS, et al. Stakeholder Perspectives on Potential Open-Label Bias in Patient-Reported Outcome Results From Cancer Clinical Trials: Evidence From the IMPROvE Project. Value in Health. 2026;29(11):2044-2053. doi:10.1016/j.jval.2026.06.002

BibTeX
@article{Efficace2026,
  author = {Efficace, Fabio and Krepper, Daniela and Sparano, Francesco and Aaronson, Neil K and Cella, David and Collins, Gary S and Giesinger, Johannes M and Chakraborty, Rajshekhar and Di Maio, Massimo and Anota, Amelie},
  title = {Stakeholder Perspectives on Potential Open-Label Bias in Patient-Reported Outcome Results From Cancer Clinical Trials: Evidence From the IMPROvE Project},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {11},
  pages = {2044--2053},
  doi = {10.1016/j.jval.2026.06.002}
}
Kostenlos starten →